Generic Name: maraviroc
Common side effects of Selzentry include: upper respiratory tract infection and skin rash.  See below for a comprehensive list of adverse effects.
Applies to maraviroc: oral tablet
As well as its needed effects, maraviroc (the active ingredient contained in Selzentry) may cause unwanted side effects that require medical attention. 
If any of the following side effects occur while taking maraviroc, check with your doctor immediately:
Some maraviroc side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:


Applies to maraviroc: oral liquid, oral tablet
The most common side effects reported with twice-daily treatment were cough, pyrexia, upper respiratory tract infections, rash, and dizziness.  The most common side effects reported with once-daily dosing were diarrhea, edema, influenza, esophageal candidiasis, sleep disorders, rhinitis, parasomnias, and urinary abnormalities.  Nausea, diarrhea, fatigue, and headache were common in Phase 2b/3 trials.[Ref]
Very common (10% or more): Upper respiratory tract infection (up to 32%), coughing and associated symptoms (14%), bronchitis (up to 13%)Common (1% to 10%): Upper respiratory tract signs/symptoms, sinusitis, upper respiratory tract signs/symptoms, nasal congestion and inflammations, breathing abnormalities, paranasal sinus disorders, lower respiratory tract and lung infections, pneumonia, influenzaFrequency not reported: Rhinitis, bronchospasm and obstruction, respiratory tract disorders, epistaxis[Ref]
Very common (10% or more): Pyrexia (13%)Common (1% to 10%): Asthenia, herpes infection, bacterial infections, herpes zoster/varicella, pain and discomfort, Neisseria infections, viral infections, body temperature perception, ear disorders, otitis mediaFrequency not reported: Edema, fatigue, hot flushes, condyloma acuminatum, treponema infections, septic shock[Ref]
Very common (10% or more): Rash (up to 11%)Common (1% to 10%): Nail and nail bed conditions (excluding infections and infestations), apocrine and eccrine gland disorders, pruritus, folliculitis, tinea infections, lipodystrophies, acnes, erythemas, alopeciasFrequency not reported: Dermatitis, eczemaPostmarketing reports: Severe skin reactions (including Stevens-Johnson syndrome, drug rash with eosinophilia and systemic symptoms [DRESS], toxic epidermal necrolysis)[Ref]
Severe, potentially life-threatening skin and hypersensitivity reactions were characterized by rash, constitutional findings, and sometimes organ dysfunction, including hepatic failure.  In most cases, other drugs associated with such reactions were coadministered.[Ref]
Severe, potentially life-threatening skin and hypersensitivity reactions were characterized by rash, constitutional findings, and sometimes organ dysfunction, including hepatic failure.  In most cases, other drugs associated with such reactions were coadministered.[Ref]
Postmarketing reports: Severe hypersensitivity reactions[Ref]
Elevated amylase (greater than 2 to 5 times upper limit of normal [ULN]: up to 5.7%; greater than 5 times ULN: up to 0.3%) and elevated lipase (greater than 2 to 5 times ULN: 5%; greater than 5 times ULN: 1.3%) have been reported.[Ref]
Very common (10% or more): Flatulence, bloating, and distention (10%)Common (1% to 10%): Gastrointestinal atonic and hypomotility disorders, constipation, elevated amylase, elevated lipase, gastrointestinal signs/symptoms, abdominal pain, flatulence, nauseaUncommon (0.1% to 1%): Esophageal candidiasisFrequency not reported: Diarrhea, gastrointestinal pain, dyspeptic signs/symptoms, ulceration stomatitis, gingivitis, dry mouth, vomiting, Clostridium difficile colitis[Ref]
Common (1% to 10%): Dizziness/postural dizziness, paresthesias and dysesthesias, sensory abnormalities, disturbances in consciousness, peripheral neuropathies, memory loss (excluding dementia)Uncommon (0.1% to 1%): Seizures and seizure disorders/convulsions and epilepsyFrequency not reported: Headache, sleep disorders, syncope, cerebrovascular accident, tremor (excluding congenital), facial palsy, hemianopia, loss of consciousness, viral meningitis, meningitis, visual field defect[Ref]
Common (1% to 10%): Anemias, decreased absolute neutrophil count, neutropenias, decreased hemoglobinRare (0.01% to 0.1%): Pancytopenia, granulocytopeniaFrequency not reported: Marrow depression, hypoplastic anemia[Ref]
Decreased absolute neutrophil count (500 to 749/mm3: up to 4.3%; less than 500/mm3: up to 1.4%) and decreased hemoglobin (6.5 to 6.9 g/dL: 0.6%; less than 6.5 g/dL: 2.3%) have been reported.[Ref]
Common (1% to 10%): Appetite disorders, anorexiaRare (0.01% to 0.1%): Increased alkaline phosphataseFrequency not reported: Unintentional weight loss (wasting), hyperlipidemia[Ref]
Common (1% to 10%): Disturbances in initiating and maintaining sleep/insomnia, depressive disorders/depression, anxiety symptomsFrequency not reported: Parasomnias, somnolence[Ref]
Common (1% to 10%): Joint-related signs/symptoms, elevated creatine kinase, muscle painsUncommon (0.1% to 1%): Myositis, increased blood creatine phosphokinaseRare (0.01% to 0.1%): Muscle atrophyFrequency not reported: Infective myositis, osteonecrosis, rhabdomyolysis[Ref]
Elevated creatine kinase (greater than 10 to 20 times ULN: 2.8%; greater than 20 times ULN: 1.1%) has been reported.[Ref]
Elevated total bilirubin (greater than 2 to 5 times ULN: 5%; greater than 5 times ULN: 5.5%), elevated AST (greater than 5 times ULN: up to 4.8%; greater than 10 times ULN: up to 1.7%), and elevated ALT (greater than 5 times ULN: up to 3.9%; greater than 10 times ULN: up to 1%) have been reported.[Ref]
Common (1% to 10%): Elevated total bilirubin, elevated AST, elevated ALTUncommon (0.1% to 1%): Hyperbilirubinemia, elevated GGTRare (0.01% to 0.1%): Toxic hepatitis, hepatic failure, hepatic cirrhosisVery rare (less than 0.01%): Hepatic failure with allergic featuresFrequency not reported: Hepatotoxicity (sometimes associated with rash and eosinophilia), cholestatic jaundice, portal vein thrombosis, hypertransaminasemia, jaundice[Ref]
Common (1% to 10%): Bladder and urethral symptoms, urinary tract signs/symptoms, erection and ejaculation conditions and disorders, anogenital wartsUncommon (0.1% to 1%): ProteinuriaFrequency not reported: Urinary abnormalities[Ref]
Common (1% to 10%): Vascular hypertensive disordersRare (0.01% to 0.1%): Angina pectorisFrequency not reported: Postural/orthostatic hypotension, arrhythmia, unstable angina, acute cardiac failure, coronary artery disease, coronary artery occlusion, endocarditis, myocardial infarction, myocardial ischemia[Ref]
Common (1% to 10%): Skin neoplasmsRare (0.01% to 0.1%): Malignant bile duct neoplasms/bile duct cancer, diffuse large B-cell lymphoma, Hodgkin's disease, metastases to bone, metastases to liver, metastases to peritoneum, esophageal carcinoma, nasopharyngeal carcinoma/cancerFrequency not reported: Abdominal neoplasm, anal cancer, anaplastic large cell lymphomas (T- and null-cell types), endocrine neoplasms (malignant and unspecified), basal cell carcinoma, Bowen's disease, cholangiocarcinoma, lymphoma, squamous cell carcinoma, squamous cell carcinoma of skin, tongue neoplasm (unspecified malignant stage)[Ref]
Common (1% to 10%): Conjunctivitis; ocular infections, inflammations, and associated manifestationsFrequency not reported: Abnormal vision, eye pain[Ref]
Uncommon (0.1% to 1%): Renal failure[Ref]
Frequency not reported: Immune reconstitution syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome)[Ref]
1. HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Office of AIDS Research Advisory Council (OARAC). NIH. National Institutes of Health "Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available from: URL: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf."   ([2013 Feb 12]):
2. "Product Information. Selzentry (maraviroc)." Pfizer U.S. Pharmaceuticals Group, New York, NY. 
3. Yost R,  Pasquale TR,  Sahloff EG "Maraviroc: A coreceptor CCR5 antagonist for management of HIV infection." Am J Health Syst Pharm 66 (2009): 715-26
4. HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. National Institutes of Health "Guidelines for the use of antiretroviral agents in pediatric HIV infection. Available from: URL: http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf."   ([2014 Feb 12]):
5. Lieberman-Blum SS,  Fung HB,  Bandres JC "Maraviroc: A CCR5-receptor antagonist for the treatment of HIV-1 infection." Clin Ther 30 (2008): 1228-50
6. Cerner Multum,  Inc. "Australian Product Information." O 0
7. Fatkenheuer G,  Pozniak AL,  Johnson MA, et al. "Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1." Nat Med 11 (2005): 1170-2
8. "Drugs for HIV infection." Treat Guidel Med Lett 7 (2009): 11-22
9. "Two new drugs for HIV infection." Med Lett Drugs Ther 50 (2008): 2-4
10. Abel S,  van der Ryst E,  Rosario MC, et al. "Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers." Br J Clin Pharmacol 65 Suppl 1 (2008): 5-18
11. "Anti-HIV agents. Maraviroc--coming soon." TreatmentUpdate 19 (2007): 2-4
12. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0
13. Borras-Blasco J,  Navarro-Ruiz A,  Borras C,  Castera E "Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection." J Antimicrob Chemother 62 (2008): 879-88
14. Abel S,  Russell D,  Whitlock LA,  Ridgway CE,  Muirhead GJ "The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers." Br J Clin Pharmacol 65 Suppl 1 (2008): 47-53
15. Macarthur RD,  Novak RM "Maraviroc: The First of a New Class of Antiretroviral Agents." Clin Infect Dis 47 (2008): 236-41
It is possible that some side effects of Selzentry may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

Body aches or pain
burning or stinging of the skin
chills
cough producing mucus
coughing
difficulty with breathing
dizziness when getting up suddenly from a lying or sitting position
ear congestion
headache
loss of voice
pain or tenderness around the eyes and cheekbones
painful blisters on the trunk of the body
painful cold sores or blisters on the lips, nose, eyes, or genitals
shortness of breath or troubled breathing
sneezing
sore throat
stuffy or runny nose
tightness of the chest or wheezing
unusual tiredness or weakness


Abdominal or stomach pain or tenderness
arm, back, or jaw pain
black, tarry stools
blood in the urine
blurred or double vision
burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
burning, dry, or itching eyes
burning, itching, and pain in the hairy areas, pus at the root of the hair
change in consciousness
chest pain, discomfort, or heaviness
choking
clay-colored stools
cold, clammy skin
confusion
convulsions
dark-colored urine
diarrhea
dilated neck veins
discharge or excessive tearing
dizziness
drowsiness
earache
extreme fatigue
eye pain
fast, weak pulse
fever
frequent urge to urinate
general feeling of discomfort or illness
general feeling of tiredness or weakness
heavy jaw feeling
inability to speak
increased frequency of urination
irregular breathing
itching
joint pain
light-colored stools
lightheadedness
loosening of a tooth
loss of appetite
loss of bladder control
loss of taste
lumps in the tongue
muscle aches, pains, or stiffness
muscle cramps or spasms
nausea or vomiting
nervousness
noisy breathing
pain or burning during urination
pain or discomfort in the arms, jaw, back, or neck
pain, swelling, or numbness in the mouth or jaw
pale skin
pounding in the ears
rash
redness or swelling in the ear
redness, pain, swelling of the eye, eyelid, or inner lining of the eyelid
sensitivity of the eye to light
severe abdominal or stomach cramps and pain
severe or sudden headache
shakiness in the legs, arms, hands, or feet
shivering
skin lumps
slow, fast, or irregular heartbeat
slurred speech
spread of cancer to the liver
stiff neck or back
stomach lumps
stomach pain, continuing
sudden loss of consciousness
sweating
swelling of the face, fingers, feet, or lower legs
swollen glands
tearing
temporary blindness
trembling or shaking of the hands or feet
trouble sleeping
troubled breathing with exertion
unable to speak
unpleasant breath odor
unsteadiness or awkwardness
unusual bleeding or bruising
vomiting of blood
warts on the genital area
watery and severe diarrhea, which may also be bloody
weakness in the arms, hands, legs, or feet
weakness on one side of the body, sudden and severe
weight gain
weight loss
yellow eyes or skin


Blistering, peeling, or loosening of the skin
cough
muscle pain
red skin lesions, often with a purple center
red, irritated eyes
sores, ulcers, or white spots in the mouth or on the lips


Difficulty having a bowel movement (stool)
difficulty with moving
increased or decreased appetite
swelling or redness in the joints


Acid or sour stomach
belching
blistering, crusting, irritation, or reddening of the skin
canker sores
discouragement
feeling sad or empty
flushing or redness of the skin
heartburn
indigestion
irritability
loss of interest or pleasure
redistribution or accumulation of body fat
skin rash, encrusted, scaly, and oozing
sores, ulcers, or white spots on the lips or tongue or inside the mouth
stomach discomfort or upset
tiredness
trouble in concentrating
unusually warm skin

